Nlrp3 Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
NLRP3 NLRP3 (NLR family pyrin domain containing 3) is an inflammasome component. Critical for neuroinflammation in AD, PD, and MS.
Chromosomal location: 1q44
NLRP3 mutations or dysregulation contribute to neurodegenerative diseases through various mechanisms.
Modulating NLRP3 expression or function may have therapeutic potential for neurodegenerative disease treatment.
Symbol: NLRP3
Full Name: NLR Family Pyrin Domain Containing 3
Chromosomal Location: 1q44
NCBI Gene ID: 114548
Ensembl ID: ENSG00000162711
UniProt ID: Q9N2R8
OMIM: 606416
NLRP3 (also known as NALP3 or cryopyrin) is a key component of the NLRP3 inflammasome, a multiprotein complex that activates caspase-1 and leads to the maturation of pro-inflammatory cytokines IL-1β and IL-18[1].
The NLRP3 inflammasome consists of:
NLRP3 can be activated by:
NLRP3 plays a significant role in AD pathogenesis:
In PD, NLRP3 is implicated in:
NLRP3 inflammasome activation in ALS:
NLRP3 gain-of-function mutations cause CAPS:
NLRP3 is expressed in:
In the brain, NLRP3 is primarily expressed in microglia and is upregulated in response to pathological stimuli.
Several NLRP3 inhibitors are in development:
Drugs targeting IL-1 pathway:
For neurodegeneration, modulating NLRP3 could reduce harmful neuroinflammation.
Martinon F, et al. (2002). "The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-β." Mol Cell. 10(2):417-426. DOI:10.1016/S1097-2765(0200599-3[1:1]
Heneka MT, et al. (2013). "NLRP3 is activated in Alzheimer's disease and contributes to pathology in APP/PS1 mice." Nature. 493(7434):674-678. [DOI:10.1038/nature11729^2]
Sun L, et al. (2020). "NLRP3 deficiency attenuates Parkinson's disease via autophagy." Brain Res. 1727:146530. [DOI:10.1016/j.brainres.2019.146530^3]
Johansson J, et al. (2020). "NLRP3 inflammasome in ALS - a promising therapeutic target?" Pharmacol Ther. 212:107553. [DOI:10.1016/j.pharmthera.2020.107553^4]
The study of Nlrp3 Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Martinon F, et al. (2002). "The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-β." Mol Cell. 10(2):417-426. DOI:10.1016/S1097-2765(0200599-3 ↩︎ ↩︎
Heneka MT, et al. (2013). "NLRP3 is activated in Alzheimer's disease and contributes to pathology in APP/PS1 mice." Nature. 493(7434):674-678. DOI:10.1038/nature11729 ↩︎
Sun L, et al. (2020). "NLRP3 deficiency attenuates Parkinson's disease via autophagy." Brain Res. 1727:146530. DOI:10.1016/j.brainres.2019.146530 ↩︎
Johansson J, et al. (2020). "NLRP3 inflammasome in ALS - a promising therapeutic target?" Pharmacol Ther. 212:107553. DOI:10.1016/j.pharmthera.2020.107553 ↩︎